Skip to main content

Table 2 Baseline characteristics of the participants at step 2 randomisation

From: Optimising first- and second-line treatment strategies for untreated major depressive disorder — the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial

  Continue with sertraline (n = 551) Combine sertraline with mirtazapine (n = 537) Switch to mirtazapine (n = 558)
Demographic characteristics
 Age, year mean (SD) 41.5 (11.6) 42.0 (11.7) 41.4 (11.4)
 Female sex, n (%) 289 (52.5) 284 (52.9) 281 (50.4)
 Education year, mean (SD) 14.1 (2.4) 13.8 (2.2) 14.1 (2.3)
 Job status, n (%)
  Employed full-time 213 (38.7) 218 (40.8) 215 (38.7)
  Employed part-time 52 (9.4) 52 (9.7) 40 (7.2)
  On medical leave 146 (26.5) 143 (26.7) 163 (29.3)
  Housewife 47 (8.5) 62 (11.6) 53 (9.5)
  Student 3 (0.5) 3 (0.6) 8 (1.4)
  Retired 6 (1.1) 5 (0.9) 4 (0.7)
  Not employed 84 (15.3) 52 (9.7) 73 (13.1)
  Missing 0 2 2
 Marital status, n (%)
  Single, never married 188 (34.2) 144 (26.9) 188 (33.7)
  Single, divorced or separated 75 (13.6) 182 (15.3) 80 (14.3)
  Single, widowed 10 (1.8) 17 (3.2) 9 (1.6)
  Married 277 (50.4) 292 (54.6) 281 (50.4)
  Missing 1 2 0
Clinical characteristics
 Age of onset at first episode, years, mean (SD) 37.0 (12.9) 37.0 (12.8) 36.4 (12.4)
 Number of previous depressive episodes, mean (SD), range 2.4 (3.4), 1–30 2.1 (3.2), 1–50 2.4 (4.2), 1–50
 Length of current episode, months, mean (SD), range 5.7 (10.6), 0.5–139 6.7 (16.9), 0.5–240 6.5 (16.3), 0.5–276
 Inpatient status at baseline, n (%) 1 (0.2) 1 (0.2) 2 (0.4)
 PHQ-9 at week 3, mean (SD) 12.8 (5.2) 12.6 (5.1) 12.8 (5.2)
 BDI-II at week 3, mean (SD) 24.5 (10.7) 24.1 (10.7) 24.4 (10.9)
 Sertraline at week 3, mean (SD), mg/day 72.2 (26.6) 71.4 (27.6) 72.6 (28.3)
  1. BDI-II Beck Depression Inventory 2nd edition, PHQ-9 Patient Health Questionnaire-9